Alexion Pharma pauses further enrollment in COVID-19 drug study

added 14.01.2021 00:17

Image of article 'Alexion Pharma pauses further enrollment in COVID-19 drug study'
Share

Alexion Pharmaceuticals Inc.

Alexion shares declined 0.3% after hours, following a 0.5% rise in the regular session to close at $156.44.

Alexion said it will continue treating current patients and that no new safety concerns were found.

ALXN, said late Wednesday it stopped enrolling patients in a clinical study testing a treatment for severe COVID-19 patients based on the recommendation of a data monitoring board.

Similar Posts